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Impaired Coronary Microvascular Functions in Patients With Behçet Disease
To the Editor: Vascular involvement is well known characteristic
of Behçet disease (BD), which is a multisystem inflammatory
disease (1). Coronary vascular involvement resulting in acute
myocardial infarction without coronary atherosclerosis and in an
increased prevalence of silent myocardial ischemia has been re-
ported in BD patients with angiographically normal coronary
arteries (2,3). We hypothesized that BD, which causes several
cardiovascular complications, might cause coronary microvascular
dysfunction, therefore impairing coronary flow reserve (CFR).
Subjects with BD were diagnosed according to the International
Study Group Criteria (4). Inclusion criteria were having BD
without any previous vascular involvement. Exclusion criteria were
any identifiable factor that might cause coronary microvascular
dysfunction, such as diabetes mellitus, hypertension, hyperlipid-
emia, smoking, drinking alcohol, using any vasoactive drug,
corticosteroids, and/or methotrexate therapy.
Fulfilling the criteria, 33 patients with BD who had had at least
15 lesion-free days were admitted for the study. For the control
group, 40 age- and gender-matched healthy subjects were entered
from our hospital staff. Written informed consent was obtained
from each subject, and the institutional ethics committee approved
the study protocol.
Transthoracic Doppler harmonic echocardiographic examina-
tion was performed on each subject using an Acuson Sequoia C256
Echocardiography System (Acuson, Mountain View, California)
equipped with a high-resolution transducer with second harmonic
capability (5V2c). Coronary diastolic peak velocities of the left
anterior descending coronary artery were measured at baseline and
after dipyridamole infusion (0.84 mg/kg over 6 min). By averaging
the three highest Doppler signals for each measurement, CFR was
defined as the ratio of hyperemic to baseline diastolic peak
velocities (5). One investigator, blinded to the study’s parameters,
performed all of the measurements. Images were recorded on VHS
videotapes. Two experienced echocardiographers analyzed the
recordings.
The analyses were performed using SPSS for Windows version 9.0
(SPSS Inc., Chicago, Illinois). Comparison analyses were made using
the Student t test and the Mann-Whitney U test when appropriate. The
Pearson correlation test was used to search possible associations. Stepwise
linear regression analysis was performed to identify the independent
associations of CFR. All p values 0.05 were considered significant.
The two groups were similar regarding age, body mass index, total
cholesterol, high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein cholesterol, and high-sensitivity C-reactive protein values
(Table 1). Mitral E velocity and mitral A velocity were similar
between the 2 groups; however, the mitral E/A ratio was lower in BD
patients (1.33  0.30 vs. 1.52  0.37; p  0.030), indicating left
ventricular diastolic dysfunction (Table 1). Resting coronary diastolic
peak flow velocity values were similar between the 2 groups (24.2 
7.5 vs. 23.6  3.6; p  0.629). Hyperemic coronary diastolic peak
flow velocity values tended to differ between the 2 groups, although
not statistically significantly (61.2 17.5 vs. 67.4 13.3, p 0.093).
The CFR values were significantly different between the 2 groups
(2.55  0.46 vs. 2.87  0.53, p  0.013) (Table 1). When the BD
group was divided into 2 subgroups, the BD patients on colchicine
treatment (27 patients) and the BD patients without treatment, the
Mann-Whitney U test showed that the CFR values of the 2 groups
were similar (2.52  0.42 vs. 2.58  0.51, p  0.744).
In 3 of the 33 subjects, the CFR value was 2.0, and in 13 of
the subjects the CFR value was 2.5. When the subjects were
divided into 2 subgroups, the subjects with CFR 2.5 and the
subjects with CFR 2.5, HDL cholesterol (39.1  8.0 vs. 44.2 
9.8, p  0.067) was lower in the subjects with CFR 2.5, and
disease duration was higher in the subgroup of subjects with CFR
2.5 (74.8  54.9 vs. 58.7  38.5, p  0.560).
The Pearson correlation analysis showed that in BD patients (33
patients), CFR correlated significantly with BD duration (r 
0.511, p  0.002), HDL cholesterol level (r  0.445, p  0.009),
age, and body mass index (r  0.396, p  0.022). The mitral E/A
ratio correlated significantly with age, systolic blood pressure, diastolic
Table 1. Demographic, Biochemical, and Coronary Flow Measurements of Behçet Disease
Patients and Control Group
Behçet Disease
(n  33)
Control Subjects
(n  40) p Value
Age (yrs) 35.0  10.3 38.1  7.9 0.131
Disease duration (months) 66.5  46.3 —
Body mass index 24.8  3.3 25.4  3.5 0.442
Total cholesterol (mg/dl) 168.3  28.8 180.8  54.4 0.336
Triglycerides (mg/dl) 123.6  58.3 116.9  57.0 0.663
HDL cholesterol (mg/dl) 42.8  9.2 44.7  9.1 0.417
LDL cholesterol (mg/dl) 100.7  23.4 106.1  23.0 0.377
hsCRP (mg/dl) 3.1  4.7 2.0  1.5 0.144
Homocysteine (mol/l) 11.19  3.04 8.92  2.96 0.057
Resting DPFV (cm/s) 24.2  7.5 23.6  3.6 0.629
Hyperemic DPFV (cm/s) 61.2  17.5 67.4  13.3 0.093
CFR 2.55  0.46 2.87  0.53 0.013
Mitral E/A ratio 1.33  0.30 1.52  0.37 0.030
CFR  coronary flow reserve; DPFV  coronary diastolic peak flow velocity; HDL  high-density lipoprotein; hsCRP 
high-sensitivity C-reactive protein; LDL  low-density lipoprotein.
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blood pressure, and left ventricular mass index; however, not signifi-
cantly with BD duration (r  0.314, p  0.075) (Table 2).
When CFR was entered as a dependent variable and age, body
mass index, BD duration, and HDL cholesterol were entered as
independent variables in a stepwise linear regression model, disease
duration (  453, p  0.005) and HDL cholesterol value ( 
0.335, p  0.033) were independent predictors of CFR (standard
error of the estimate 0.375, R2 0.390, total significance 0.002).
In this study, we found that CFR is impaired in BD patients.
Chambers et al. (6) established endothelial dysfunction by showing
impaired brachial artery flow-mediated dilation. Turkolmez et al. (3)
have investigated the prevalence of silent myocardial ischemia in BD
patients. They have found that an exercise electrocardiogram showed
ischemic changes in 8 of 41 BD patients and in 1 of 35 control
patients. Silent myocardial ischemia was found in those 8 (19.5%)
patients with BD and 1 (2.9%) in a control group with thallium-201
myocardial perfusion scintigraphy. In this study, the mean duration of
BD was higher in the patients with silent myocardial ischemia. In our
study, confirming the result of Turkolmez et al. (3), we found an
association between BD duration and CFR. Additionally, linear
regression analysis showed that BD duration and HDL cholesterol
value were independent predictors for the CFR values of BD patients.
The pathophysiology of silent ischemia in BD patients is unclear. Our
finding that BD patients have impaired coronary flow reserve com-
pared with healthy control patients may be an explanation for the
silent myocardial ischemia. In their study, Turkolmez et al. (3)
performed coronary angiography in patients with silent myocardial
ischemia, but they did not find any significant coronary stenosis in
patients with BD. Our results implicate that the silent myocardial
ischemia suggested by Turkolmez et al. (3) might have been related
to an impairment of coronary microvascular function.
In conclusion, our study showed that coronary microvascular
function and, therefore, CFR, is impaired in BD patients without
a previous vascular manifestation. The independent predictors for
CFR in BD patients are disease duration and HDL cholesterol
values. Impaired CFR might have been one of the causes of
cardiovascular manifestations in BD patients.
In this study, we have excluded subjects with known coronary
risk factors and patients with known previous vascular manifesta-
tions. Additionally, we did not perform coronary angiography on
the subjects; therefore, it cannot be precisely suggested that these
subjects are free of coronary atherosclerosis, and the study does not
provide information about BD effects on CFR in patients with
coronary risk factors.
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Table 2. Correlations Between Coronary Flow Reserve and the Other Study Variables
Correlations
With r and p
Total
Cholesterol HDL LDL
BD
Duration hsCRP ESR
Mitral E/A
Ratio Age BMI
CFR 0.225 0.445 0.141 0.511 0.148 0.146 0.047 0.422 0.396
0.209 0.009 0.435 0.002 0.412 0.417 0.795 0.015 0.022
Total cholesterol 0.293 0.694 0.102 0.240 0.062 0.373 0.437 0.177
0.097 0.001 0.574 0.176 0.727 0.033 0.011 0.324
HDL 0.060 0.097 0.145 0.158 0.047 0.154 0.388
0.738 0.593 0.420 0.381 0.794 0.391 0.026
LDL 0.047 0.182 0.030 0.318 0.369 0.083
0.795 0.309 0.865 0.071 0.070 0.692
BD duration 0.237 0.215 0.327 0.179 0.246
0.184 0.229 0.063 0.318 0.167
hsCRP 0.564 0.015 0.023 0.225
0.001 0.936 0.905 0.241
ESR 0.047 0.037 0.042
0.795 0.848 0.829
E/A 0.457 0.117
0.007 0.518
Age 0.340
0.053
BD  Behçet disease; BMI  body mass index; ESR  erythrocyte sedimentation rate; other abbreviations as in Table 1.
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